In recent years there has been a dramatic increase in the discovery of information related to the genetic risk of disease, as well as in the technical ability to accurately measure an individual's genotype. These advances underlie the promise of personalized medicine, in which a patient's genotype informs the medical care they receive. Private companies are attempting to capitalize on these advances by providing direct-to-consumer (DTC)6 genetic testing that estimates the risk of disease for a customer, given their genotype. Because these tests make claims about medical conditions, they have come under scrutiny by regulatory agencies.​​

In a previous issue of Clinical Chemistry, experts discussed Direct-to-Consumer Genetic Testing in this Q&A (free to access). We’d like to get your views on the topic: Do you think the genetic testing offered by DTC companies should require direct physician involvement? What about genetic counseling by certified counselors?​

Share your opinion on this topic below. Be sure to check out all of our Q&As here.​